Sotio terminates three trials studying its IL-15 superagonist due to ‘insufficient efficacy’
Czech biotech Sotio is immediately scrapping three clinical trials of its interleukin-15 superagonist called nanrilkefusp alfa after interim data showed “insufficient efficacy.”
“While we are disappointed with this outcome, we will continue to gather and analyze the full body of data from these studies to inform our future development plans for nanrilkefusp alfa,” Sotio chief medical officer Richard Sachse said in a press release.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.